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Background
HNC is immunosuppressive, with low absolute lympho-
cyte counts, impaired activity of effectors such as natural
killer cells (NK), and poor antigen-presenting function.
The anti-EGFR monoclonal antibody cetuximab (CTX)
prolongs survival in HNC, but only in a subset of
patients. The clinical activity of CTX has been mechan-
istically linked to NK-mediated antibody-dependent cel-
lular cytotoxicity (ADCC). However, recent data has
shown that CTX increases the frequency of intratumoral
CTLA-4+FoxP3+ regulatory T cells (Treg), which sup-
press ADCC and are associated with poor clinical out-
come. In ex vivo experiments, this effect could be
attenuated by targeting CTLA-4 on Tregs. Therefore it
is possible that the clinical efficacy of CTX may be
improved by strategies to enhance the activation of the
immune system or inhibit the Treg suppressive effects.
Motolimod (formerly VTX-2337) is a novel Toll-like
receptor 8 (TLR8) agonist which stimulates myeloid
dendritic cells (mDC), monocytes, and NK. Preclinical
data have demonstrated enhanced CTX and NK-
mediated lysis of HNC cells and dendritic cross-prim-
ing of EGFR-specific CD8+ T cells. CTX and motoli-
mod in HNC patients was tolerable and active in a
Phase Ib study, with enhanced mobilization and activa-
tion of NK cells. The central hypothesis in this study
is that NK and monocyte/mDC activation by CTX is
enhanced by concomitant administration of motoli-
mod, thereby amplifying the innate and adaptive
immune response in the circulation and in the tumor
microenvironment.
Methods
This is a prospective Phase Ib clinical trial (NCT02124850)
of preoperative treatment with CTX and motolimod. The
primary objective is to determine the extent to which the
administration of neoadjuvant CTX plus motolimod mod-
ulates immune biomarkers in peripheral blood and HNC
tumors. An exploratory objective of the study is to assess
whether this modulation of biomarkers can predict anti-
tumor response. Subjects must have HNC stage II– IVA
and be surgical candidates. CTX and motolimod will be
administered for a 3–4 week preoperative period. The bio-
marker modulation and biopsies of skin/acneiform rash
will be studied in correlation with clinical response by CT
or MRI scan. Tumor apoptosis/proliferation will be
assessed by biopsy pre- and post-treatment with CTX/
motolimod. All patients will receive definitive surgical
resection. Enrollment target is fifteen complete specimens
(tumor, peripheral blood mononuclear cells and serum). A
pending amendment will assess the impact of adding
checkpoint inhibition to the CTX/motolimod combination.
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